Login / Signup

Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.

Wen GaoYuan JianJuan DuXiaozhe LiHuixing ZhouZhi-Yao ZhangGuangzhong YangGuorong WangYing TianYanchen LiYin WuWeijun FuJuan LiWenming Chen
Published in: Cancer medicine (2020)
In conclusion, 1q21 gain is an adverse prognostic factor for MM patients received ASCT.
Keyphrases
  • prognostic factors
  • stem cell transplantation
  • multiple myeloma
  • high dose
  • end stage renal disease
  • bone marrow
  • chronic kidney disease
  • emergency department
  • ejection fraction
  • patient reported